Reviva Pharmaceuticals Holdings Inc
RVPH
View Detailed Chart
0.286USD
+0.031+12.35%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
27.60MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+12.35%
5 Days
-2.02%
1 Month
-11.33%
6 Months
-36.33%
Year to Date
+2.69%
1 Year
-86.16%
View Detailed Chart
TradingKey Stock Score of Reviva Pharmaceuticals Holdings Inc
Currency: USD Updated: 2026-02-06Key Insights
Reviva Pharmaceuticals Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 181 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.56.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Reviva Pharmaceuticals Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Reviva Pharmaceuticals Holdings Inc Highlights
StrengthsRisks
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Overvalued
The company’s latest PE is -0.65, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.79M shares, decreasing 27.11% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 3.20M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.43.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
5.563
Target Price
+2081.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Reviva Pharmaceuticals Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Reviva Pharmaceuticals Holdings Inc Info
Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Ticker SymbolRVPH
CompanyReviva Pharmaceuticals Holdings Inc
CEOBhat (Laxminarayan)
Websitehttps://revivapharma.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70708.030
+737.900 (+1.05%)
282.580
+22.390 (+8.61%)
2082.000
+30.270 (+1.47%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
